Abstract
Objectives The character and duration of cognitive adverse effects of electroconvulsive therapy (ECT) are unclear. This study investigated (1) the sensitivity of a short cognitive test battery to cognitive adverse effects of ECT, (2) the relation between subjective and objective cognitive adverse effects, and (3) patient characteristics associated with more subjective than objective adverse effects. Methods Forty-one patients with unipolar or bipolar depression referred to ECT underwent assessments at baseline, 5 to 7 days post-ECT, and 3 months post-ECT. Patients rated their fear of various aspects of ECT on a visual analog scale. At each assessment, patients were evaluated for depressive symptoms, completed the Screen for Cognitive Impairment in Psychiatry (SCIP) and Trail Making Test-Part B (TMT-B), and rated their cognitive difficulties. Results Patients feared cognitive adverse effects and lack of treatment efficacy more than other aspects of ECT. The SCIP and TMT-B revealed transient decline in objective cognition after ECT, which was reversed after 3 months. Patients presented with more subjective than objective cognitive difficulties at baseline and more subjective than objective cognitive adverse effects of ECT. This discrepancy was significantly reduced at follow-up. Younger age and poorer objective cognition pretreatment were associated with more subjective than objective cognitive adverse effects 5 to 7 days after ECT. Conclusions The SCIP and TMT-B are sensitive to cognitive adverse effects of ECT. Patients show more subjective than objective cognitive adverse effects of ECT. These insights can be used clinically to inform patients of treatment choice and expected cognitive consequences.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Journal of ECT |
Vol/bind | 38 |
Udgave nummer | 1 |
Sider (fra-til) | 30-38 |
Antal sider | 9 |
ISSN | 1095-0680 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:K.M.W. holds a 5-year Lundbeck Foundation Fellowship (grant R21520154121) and a grant from the Weiman Foundation. L.G.H. has received a 1-year scholarship from the Lundbeck Foundation (grant R300-2018-1278).
Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.